Revelation Biosciences, Inc. REVB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.09M | 5.49M | 5.01M | 4.55M | 4.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.27M | 10.07M | 9.07M | 8.25M | 8.11M |
| Operating Income | -11.27M | -10.07M | -9.07M | -8.25M | -8.11M |
| Income Before Tax | -10.75M | -9.87M | -8.91M | -8.13M | -8.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.75 | -9.87 | -8.91 | -8.13 | -8.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.75M | -9.87M | -8.91M | -8.13M | -8.46M |
| EBIT | -11.27M | -10.07M | -9.07M | -8.25M | -8.11M |
| EBITDA | -11.24M | -10.04M | -9.04M | -8.22M | -8.08M |
| EPS Basic | -86.09 | -276.27 | -434.69 | -423.16 | -373.64 |
| Normalized Basic EPS | -27.73 | -77.22 | -183.99 | -176.78 | -164.16 |
| EPS Diluted | -86.09 | -276.27 | -434.69 | -423.16 | -373.64 |
| Normalized Diluted EPS | -27.73 | -77.22 | -183.99 | -176.78 | -164.16 |
| Average Basic Shares Outstanding | 1.32M | 799.10K | 352.50K | 134.80K | 40.30K |
| Average Diluted Shares Outstanding | 1.32M | 799.10K | 352.50K | 134.80K | 40.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |